阿托伐他汀对稳定期COPD患者肺功能、肺动脉压及相关指标影响的Meta分析

发布时间：2018-04-29 13:43

本文选题：阿托伐他汀 + 慢性阻塞性肺疾病　；参考：《中国药房》2017年33期

【摘要】：目的:系统评价阿托伐他汀对稳定期慢性阻塞性肺疾病(COPD)患者肺功能、肺动脉压及相关指标的影响,为临床提供循证参考。方法:计算机检索Cochrane图书馆、PubMed、EMBase、相关期刊论文、中文科技期刊数据库,收集阿托伐他汀联合常规基础方案(试验组)对比单纯常规基础方案(对照组)治疗稳定期COPD的随机对照试验(RCT),提取资料并按照Cochrane系统评价员手册5.1.0评价质量后,采用Rev Man 5.3统计软件进行Meta分析。结果:共纳入7项RCT,合计371例患者。Meta分析结果显示,试验组患者第1秒用力呼气容积[MD=0.07,95%CI(0.04,0.09),P0.001]、第1秒用力呼气容积占预计值百分比[MD=6.18,95%CI(2.23,10.12),P=0.002]、6分钟步行距离[MD=55.31,95%CI(36.44,74.18),P0.001]均显著高于/长于对照组,肺动脉收缩压[MD=-6.78,95%CI(-11.62,-1.94),P=0.006]、平均肺动脉压[MD=-6.61,95%CI(-7.26,-5.96),P0.001]、圣乔治呼吸问卷评分[MD=-13.21,95%CI(-23.90,-2.52),P=0.02]均显著低于对照组,差异均有统计学意义;两组患者第1秒用力呼气容积占用力肺活量比值[MD=3.73,95%CI(-2.08,9.55),P=0.21]和高敏C反应蛋白水平[MD=0.29,95%CI(-1.37,1.95),P=0.73]比较,差异均无统计学意义。结论:阿托伐他汀用于稳定期COPD患者可以显著改善患者肺功能和肺动脉压,提高患者生活质量。
[Abstract]:Objective: to evaluate the effects of Atto vastatin on pulmonary function, pulmonary artery pressure and related indexes in patients with stable chronic obstructive pulmonary disease (COPD). Methods: Cochrane library was searched by computer. A randomized controlled trial of Atto vastatin combined with conventional basic regimen (trial group) was collected for the treatment of stable COPD in comparison with the control group. The data were extracted and the quality was evaluated according to the Cochrane system evaluator's manual 5.1.0. Meta analysis was carried out with Rev Man 5.3. Results: a total of 371 RCTs were included. Meta-analysis showed that the forced expiratory volume in the first second [MD0.07 ~ 95CII 0.04 ~ 0.09], the percentage of the predicted value in the first second [MD6.181.95CI2.2310.12P0.002] 6-minute walking distance [MD55.3195% CI36.444.18P0.001] were significantly higher than / longer than those in the control group. Pulmonary arterial systolic pressure (MPP) was significantly lower than that in the control group (P 0.001). The mean pulmonary arterial pressure (MPAP) was significantly lower than that in the control group (P 0.001). The score of St. George's Respiratory questionnaire was significantly lower than that in the control group (P < 0.01). The mean pulmonary artery pressure was significantly lower than that in the control group (P 0.001). The score of St. George's Respiratory questionnaire was significantly lower than that in the control group (P 0.001). There was no significant difference between the two groups in the ratio of forced expiratory volume occupying capacity to vital capacity in the first second [MDT 3.73N 95] and Gao Min C-reactive protein level (MDT 0.2995 CI-1.371.95 P0. 73). Conclusion: Atto vastatin can significantly improve pulmonary function, pulmonary artery pressure and quality of life in patients with stable COPD.
【作者单位】：镇江市第一人民医院老年科;江苏大学附属医院检验科;
【基金】：江苏大学医学临床科技发展基金资助项目(No.JLY20120169)
【分类号】：R563.9

【相似文献】